Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Source: Benzinga
Qiagen's Q1 2025 Performance: Qiagen N.V. reported a preliminary net sales growth of approximately 5% for Q1 2025, with adjusted EPS guidance raised to at least $0.55, driven by strong demand for its QuantiFERON TB test and QIAstat-Dx testing system.
2025 Outlook and Market Impact: The company anticipates achieving its mid-term target for operating income margin earlier than expected, while also facing potential challenges from U.S. import tariffs; shares rose 3.06% in premarket trading following the announcement.
Analyst Views on GNOM
Wall Street analysts forecast GNOM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNOM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 50.588
Low
Averages
High
Current: 50.588
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
